Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

MLA

Scheiner, Bernhard, et al. “Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicentre Real-World Cohort.” Alimentary Pharmacology & Therapeutics, vol. 49, no. 10, May 2019, pp. 1323–33. EBSCOhost, https://doi.org/10.1111/apt.15245.

APA

Scheiner, B., Kirstein, M. M., Hucke, F., Finkelmeier, F., Schulze, K., von Felden, J., Koch, S., Schwabl, P., Hinrichs, J. B., Waneck, F., Waidmann, O., Reiberger, T., Müller, C., Sieghart, W., Trauner, M., Weinmann, A., Wege, H., Trojan, J., Peck-Radosavljevic, M., … Pinter, M. (2019). Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Alimentary Pharmacology & Therapeutics, 49(10), 1323–1333. https://doi.org/10.1111/apt.15245

Chicago

Scheiner, Bernhard, Martha M Kirstein, Florian Hucke, Fabian Finkelmeier, Kornelius Schulze, Johann von Felden, Sandra Koch, et al. 2019. “Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicentre Real-World Cohort.” Alimentary Pharmacology & Therapeutics 49 (10): 1323–33. doi:10.1111/apt.15245.